2.4. Safety
ADVERSE EVENTS
The investigational medicinal product was given to a total of 24 people over the course of this trial, and it is worth noting that none of these participants had any treatment-emergent or significant adverse events. Furthermore, when the study drug was administered, careful vital signs and diagnostic examinations were performed. Importantly, none of these examinations indicated any clinically significant abnormalities or unusual results. It is also worth noting that no additional drugs were given during the research period, emphasizing the investigational product’s overall tolerability among this cohort of participants.